Skip to NavigationSkip to content

Business Services

Working Life: Joe Wiley, CEO, Amryt Pharma

Published on 22/10/18 at 11:47am

Pharmafocus talked to Joe Wiley, CEO and founder of Amryt Pharma as he retraced his journey from medical student in Ireland to founding a major commercial stage pharma firm...

What motivated you to originally consider and pursue a career in the pharma?

Top Ten most popular articles on this week

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with SQZ Biotech, MSD’s and Samsung Bioepis’ deal fell through. Meanwhile Pfizer announced a cull of 2% of its staff amid a widespread restructuring.

Hearing loss and inner ear disorders: The next frontier for pharmaceutical success?

Published on 18/10/18 at 12:01pm

Nawal Ouzren, CEO of Sensorion, examines the latest therapies and developments emerging in the difficult-to-treat world of human ear disorders, which paint a promising picture for patients with such conditions.

Disabling hearing loss and other inner ear disorders affect more than 360 million people worldwide, with approximately one billion additional people at risk, according to the World Health Organization. Hearing loss is triggered by many factors, with ageing and noise exposure being two of the most common causes.

Pfizer announce cull of 2% of staff

US pharma giant Pfizer is offering early retirement to American workers ahead of layoffs scheduled for next year.

The company is set to cut around 2% of its 90,000 staff as part of a restructuring intended to “simplify the organization to avoid duplication, create single points of accountability and reduce the number of layers within teams.”

The layoffs will mainly affect non-union workers. The decision has come ahead of Albert Bourla’s succession of long time Pfizer CEO Ian Read.

AI, big data: Making a case for faster drug discovery

Published on 15/10/18 at 11:58am

They’re two of the biggest buzzwords getting professionals excited across pharma – Anjali Shukla explores the ways in which AI and big data are set to galvanise the industry.

Even if you haven’t been paying attention, it is hard to miss the buzz around artificial intelligence or deep learning and how the technology is only steps away from changing lives forever. The optimism is especially significant in the pharmaceutical and healthcare industry as researchers continue to look out for cures for complex diseases.

Top Ten most popular articles on this week

Politics played a big role in pharma this week after Trump introduced legislation aimed at reducing the price of drugs. The effectiveness of trust-busting biosimilar bill in bring the medicines to market may be an interesting development over the coming year. Meanwhile the UK government came into question after researchers were denied visas.

Living with Langerhans Cell Histiocytosis

Published on 11/10/18 at 12:43pm

Affected as a young child by a rare disease which targets just one in 200,000 and led to neurodegeneration throughout her teens, Niamh ni Ruari now uses a wheelchair for mobility. She shares her story of life with her condition and a few thoughts on society’s attitudes towards the disabled community.

Can you tell me a bit about the condition, your diagnosis and the symptoms you experience?

Trump signs trust-busting biosimilar bill into law

President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of biosimilar deals to the US’ independent trust-busting agency the Federal Trade Commission (FTC).

The ruling will allow the FTC access to information regarding biosimilar agreements thus allowing the agency the ability to develop an informed strategy aimed at promoting competition in the area of biosimilars.

Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO

Published on: 09/10/18

Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen Chief Quality Officer, Senior Vice President Quality, Martin Van Trieste as their Chief Executive Officer (CEO).

Having joined Civica as a member of its board of advisors in September 2017 Van Trieste took on the position of CEO in September of this year. The experienced pharma professional brings more than 35 years of experience to the role having previously worked for pharma firms Abbot Laboratories, Amgen and Bayer.

The economics of mental health

Published on 08/10/18 at 12:01pm

Louis Goss examines mental health from a health economics and outcomes research (HEOR) perspective and asks what might be done to improve the way in which we treat medical as well as societal problems related to these conditions.

Mental health issues have been estimated to cost the world economy $2.5 trillion each year. To put that into perspective, the United Kingdom’s gross domestic product (GDP) was $2.6 trillion in 2017. Meanwhile, the world’s economy was estimated to be worth just $78.28 trillion in 2014.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches